Previous close | 26.39 |
Open | 26.45 |
Bid | 24.76 x 100 |
Ask | 24.84 x 100 |
Day's range | 24.69 - 26.83 |
52-week range | 9.44 - 36.25 |
Volume | |
Avg. volume | 1,225,261 |
Market cap | 1.269B |
Beta (5Y monthly) | 2.86 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.58 |
Earnings date | 08 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 52.20 |
On April 1, 2024, Chief Legal Officer Scott Bizily sold 8,153 shares of 4D Molecular Therapeutics Inc (NASDAQ:FDMT) according to a recent SEC Filing.
Scott Bizily, the Chief Legal Officer of 4D Molecular Therapeutics Inc (NASDAQ:FDMT), has sold 5,833 shares of the company on March 27, 2024, according to a recent SEC filing.
Conducted initial pivotal study interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA); Company has clear registration path for 4D-710 for treatment of cystic fibrosis (CF) lung disease in people with CF (pwCF) who are ineligible for or cannot tolerate approved CF modulator therapies AEROW clinical trial Phase 2 Expansion Cohort dose selection and initiation expected in Q2 2024, with pivotal trial initiation anticipated in H2 2025Initial GMP-ready suspe